Sigma-Tau Research, Inc. is a national leader in the development of compounds
used in a variety of clinical indications. Ongoing and planned research
includes applications for central and peripheral nervous system, oncology and cardiovascular
disease.
Sigma-Tau Research is developing a series of compounds, in a variety of
clinical indications, for the USA market.
- Propionyl-L-carnitine (ST 261)
This compound has completed phase III trials for Intermittent Claudication, and
an NDA is being prepared. Future development areas will focus on the
cardiovascular system.
- Acetyl-L-carnitine (ST 200)
This compound has been developed to treat both Alzheimer's disease and
peripheral diabetic neuropathy, where it has completed phase III trials.
Future areas of development will continue to revolve around cognition and
peripheral neuropathy of different origins.
- Gimatecan (ST 1481)
A camptothecin derivative, Gimatecan is in phase I-II trials for malignant
glioma and other solid tumors.
Other new chemical entities will be entering the clinical development
phase, starting in the second half of 2002, for other cardiovascular
diseases (ST 2744, ST 1326) and in oncology (PAGRIT, angiogenesis).
Click here to learn about gratifying career opportunities at Sigma-Tau Research, Inc.
Contact Sigma-Tau Research, Inc. for business development
inquires for compounds in clinical development.
|
